Celularity Inc (CELU) USD0.0001 A

Sell:$2.12Buy:$2.49$0.17 (7.46%)

Prices delayed by at least 15 minutes
Sell:$2.12
Buy:$2.49
Change:$0.17 (7.46%)
Prices delayed by at least 15 minutes
Sell:$2.12
Buy:$2.49
Change:$0.17 (7.46%)
Prices delayed by at least 15 minutes

Company Information

About this company

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Key people

Robert J. Hariri
Chairman of the Board, Chief Executive Officer
David C. Beers
Chief Financial Officer
Stephen A. Brigido
President - Degenerative Disease
John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Peter H. Diamandis
Independent Director
Shiu Fei Ling
Independent Director
Diane L. Parks
Independent Director
Click to see more

Key facts

  • EPIC
    CELU
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1511902041
  • Market cap
    $56.28m
  • Employees
    123
  • Shares in issue
    23.95m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.